IDXG / Interpace Biosciences, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 INTERPACE BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results ● Q2 Revenue of $9.2 million ● Q2 Cash Collections of $10.8 million ● Q2 Thyroid test volume up 16% year-over-year to record levels ● Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug 7, 2025 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces First Quarter 2025 Financial and Business Results ● Q1 Revenue of $11.5 million; a 13% increase year-over-year ● Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ● Q1 Thyroid test volume up 16% year-over-year to record levels ● Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ● Initiates Full Year 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 INTERPACE BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission F

Press Release, dated April 24, 2025.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OFTHE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2025 INTERPACE BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OFTHE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24249 Interpace Bios

Insider Trading Policy

Exhibit 19.1 INTERPACE BIOSCIENCES, INC. INSIDER TRADING POLICY Policy Principles 1. Employees, directors, officers and designated contractors and consultants (each a “Covered Person,” and collectively, “Covered Persons”) of Interpace Biosciences, Inc. and its direct and indirect subsidiaries (together, the “Company”) (or any other person or entity subject to this Insider Trading Policy (this “Pol

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2025 INTERPACE BIOSCI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Press Release, dated January 27, 2025

Exhibit 10.1 January 27, 2025 PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan PARSIPPANY, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) — Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its M

Fourth Amendment to Loan and Security Agreement with BroadOak Fund V, L.P., dated January 17, 2025, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 21, 2025.

Exhibit 10.1 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fourth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of January 17, 2025 between INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Corporation”), and INTERPACE DIAGNOSTICS, LLC, a Delaware limited liability company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2025 INTERPACE BIOSCI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2025 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissi

Effective 02/07/2025, Interpace Diagnostics

Exhibit 99.1 Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk PARSIPPANY, NJ, January 9, 2025 (GLOBE NEWSWIRE) – Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today responded to the final Local Coverage Determination (LCD) of Genetic Testin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 INTERPACE BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Inter

Conformed version of Certificate of Incorporation of Interpace Biosciences, Inc., as amended most recently by the Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock, effective October 11, 2024, incorporated by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2024.

Exhibit 3.1 Certificate of Incorporation of Professional Detailing, Inc. The undersigned, being a natural person, solely for the purpose of organizing a corporation under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereof and supplemental thereto, and known, identified and referre

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results ● Q3 Revenue of $12.3 million; a $3.2M and 35% increase year-over-year ● Q3 Test volume up 26% year over year to record levels ● Q3 Cash collections of $11.3M; a $1.4M and 15% increase year-over-year ● Q3 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Nov 4, 2024 (GLO

IDXG / Interpace Biosciences, Inc. / Ampersand 2018 Limited Partnership - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X303 (CUSIP Number) Ampersand 2018 Limited Partnership AMP-18 Management Company Limited Partnership AMP-18 MC LLC One Post Office Squ

IDXG / Interpace Biosciences, Inc. / 1315 Capital II, L.P. Activist Investment

SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5 )* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X 303 (CUSIP Number) 1315 Capital II, L.P. 1315 Capital Management II, LLC 2929 Walnut Street, Suite 1240 Philadelph

Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock, filed October 11, 2024.

Exhibit 3.1 INTERPACE BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW INTERPACE BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby cer

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

Exhibit 99.1 Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq PARSIPPANY, NJ, October 15, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that its Series B Preferred Stock investors, Ampersand Capital Partners and 1315 Capital (the “

Amended and Restated Investor Rights Agreement, dated as of October 10, 2024, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 15, 2024.

Exhibit 10.2 AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 10, 2024, by and among Interpace Biosciences, Inc., a Delaware corporation (the “Company”), 1315 Capital II, L.P., a Delaware limited partnership (including its successors and assigns, “1315 Capital”) and Ampersand 2018 Limited Partnership

Termination of Support Agreement, dated October 14, 2024, by and between 1315 Capital II, L.P. and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on October 15, 2024.

Exhibit 10.3 TERMINATION OF SUPPORT AGREEMENT TERMINATION OF SUPPORT AGREEMENT (this “Termination Agreement”) is entered into as of October 14, 2024, by and between 1315 Capital II, L.P., a Delaware limited partnership (“1315 Capital”), and Interpace Biosciences, Inc., a Delaware corporation (the “Company”). WHEREAS, the Company and 1315 Capital entered into that certain Support Agreement, dated a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2024 INTERPACE BIOSCI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Series C Preferred Stock Exchange Agreement, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 15, 2024.

Exhibit 10.1 EXCHANGE AGREEMENT This Exchange Agreement (this “Agreement”) is dated as of October 10, 2024, by and among Interpace Biosciences, Inc., a Delaware corporation (the “Company”), 1315 Capital II, L.P., a Delaware limited partnership (including its successors and assigns, “1315 Capital”) and Ampersand 2018 Limited Partnership, a Delaware limited partnership (including its successors and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results ● Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ● Q2 Test volume up 12% year-over-year to record levels ● Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ● Q2 Volume, Revenue, and Profitability at all-time record levels PARSIPPANY, NJ, Aug 1, 2024 (GLOB

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 INTERPACE BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission F

Interpace Biosciences Announces First Quarter 2024 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ● Q1 Revenue of $10.3 million; a 4% increase year-over-year ● Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24

Third Amendment to Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated March 29, 2024, incorporated by reference to Exhibit 10.39 of the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2024.

Exhibit 10.39

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24249 Interpace Bios

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results ● Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ● Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and 119% increase year-over-year ● Q4 and FY Adjusted EBITDA of $1.5 million and

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2024 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

IDXG / Interpace Biosciences, Inc. / Singer Douglas Mark - SINGER SCHEDULE 13G/A, AMENDMENT NO. 2 Passive Investment

SC 13G/A 1 formsc-13ga.htm SINGER SCHEDULE 13G/A, AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) * Interpace Biosciences, Inc. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 46062X303 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 INTERPACE BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ● Q3 Revenue of $9.1 million; an 11% increase year-over-year ● Q3 Test volume up 11% year-over-year ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, November 8, 2023 (GLOBE NEWSWIRE) — Interpace Biosciences,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Inter

Third Amendment to Loan and Security Agreement and Waiver, dated June 13, 2022, by and among Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Comerica Bank.

Exhibit 10.2 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT AND WAIVER This Third Amendment to Loan and Security Agreement and Waiver (this “Amendment”) is entered into as of June 13, 2022 by and between COMERICA BANK (“Bank”), INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Corporation”), INTERPACE DIAGNOSTICS

Second Amendment to Loan and Security Agreement and Waiver, dated April 22, 2022, by and among Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Comerica Bank.

Exhibit 10.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT AND WAIVER This Second Amendment to Loan and Security Agreement and Waiver (this “Amendment”) is entered into as of April 22, 2022 by and between COMERICA BANK (“Bank”), INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Corporation”), INTERPACE DIAGNOST

Fourth Amendment to Loan and Security Agreement and Waiver, dated October 31, 2022, by and among Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Comerica Bank.

Exhibit 10.3 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT AND WAIVER This Fourth Amendment to Loan and Security Agreement and Waiver (this “Amendment”) is entered into as of October , 2022 by and between COMERICA BANK (“Bank”), INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Corporation”), INTERPACE DIAGNOST

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Fifth Amendment to Loan and Security Agreement and Waiver, dated October 6, 2023, by and among Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Comerica Bank.

Exhibit 10.4 FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT AND WAIVER This Fifth Amendment to Loan and Security Agreement and Waiver (this “Amendment”) is executed on October 6, 2023 and effective as of September 30, 2023, by and among COMERICA BANK (“Bank”), INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Cor

Second Amendment to Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 24, 2023, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 27, 2023.

Exhibit 10.1 Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This Second Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of October 24, 2023 between INTERPACE BIOSCIENCES, INC., a Delaware corporation (“Parent”), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“Diagnostics Corporation”), INTERPACE DIAGNOSTICS, LLC, a Delaware limited liab

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results ● Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ● Q2 Test volume up 15% year over year to record levels ● Q2 Reimbursement improvement up 34% year-over-year driven by additional commercial contracts and collection initiatives PARSIPPANY, NJ, August 9, 2023

Employment Agreement, dated July 24, 2023, between Christopher McCarthy and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on August 2, 2023.

Exhibit 10.1 Employment Agreement This Employment Agreement (this “Agreement”) is made as of July 24, 2023 between Interpace Biosciences, Inc. (the “Company”) and Chris McCarthy (“Executive”). RECITALS WHEREAS, the Company desires to continue to retain Executive’s services, and Executive wishes to continue to be employed by the Company, pursuant to the terms and conditions set forth herein; and WH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2023 INTERPACE BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results ● Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ● Q1 Test volume up nearly 20% year over year to record levels ● Q1 41.9 million covered lives added, resulting from 8 new or updated commercial contracts PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) — Interpa

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2023 INTERPACE BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24249 Interpace Bios

Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results

Exhibit 99.1 Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results ● Q4 Revenue of $8.3 million ● Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) —Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth qua

IDXG / Interpace Diagnostics Group, Inc. / Singer Douglas Mark - SCHEDULE 13G/A, AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 formsc13ga.htm SCHEDULE 13G/A, AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Interpace Biosciences, Inc. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 46062X303 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 INTERPACE BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 000-24249 22-2919486 (State or other jurisdiction of incorporation) (Comm

Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 15, 2022.

Exhibit 10.1 AMENDMENT TO THE INTERPACE BIOSCIENCES, INC. 2019 EQUITY INCENTIVE PLAN The Interpace Biosciences, Inc. 2019 Equity Incentive Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Interpace Biosciences, Inc. (the “Company”): 1. Section 3(a) of the Plan is amended in its entirety; provided that Section 3(a)(i), as amend

Amendment to the Interpace Biosciences, Inc. Employee Stock Purchase Plan, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 15, 2022.

Exhibit 10.2 AMENDMENT TO THE INTERPACE BIOSCIENCES, INC. EMPLOYEE STOCK PURCHASE PLAN The Interpace Biosciences, Inc. Employee Stock Purchase Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Interpace Biosciences, Inc. (the “Company”): 1. Section 13.1 of the Plan is amended in its entirety; provided that Section 13.1, as amen

Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern

Exhibit 99.1 Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern ? Q3 Revenue of $8.2 million up 2% versus Prior Year ? Q3 Adjusted EBITDA Positive ? Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, November 14, 2022 (GLOBE NEWSWIRE) ?Interpace Bi

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Inter

Fourth Lease Amendment (the “Amendment”) by and between Interpace Biosciences, Inc. and Saddle Lane Realty, LLC, dated as of October 31, 2022, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 4, 2022.

EX-10.1 2 ex10-1.htm Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2022 INTERPACE BIOSCI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Severance and Consulting Agreement and General Release, dated September 30, 2022, by and between Interpace Biosciences, Inc. and Thomas Freeburg, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on October 4, 2022.

Exhibit 10.1 SEVERANCE AND CONSULTING AGREEMENT AND GENERAL RELEASE This Severance and Consulting Agreement and General Release (this ?Agreement? or this ?Agreement and General Release?), dated September 30, 2022, is entered into by Thomas Freeburg (?Executive?) and Interpace Biosciences, Inc. (the ?Company?). Executive and the Company are jointly referred to in this Agreement as the ?Parties? and

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 30, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

PRE 14A 1 formpre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by

Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.

Exhibit 99.1 August 31, 2022 Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc. ? Interpace Transitions to focused Molecular Diagnostics Business ? Disposition of Pharma Services Expected to Improve Operating Cash Flow by nearly $5 million Annually PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) ? Interpace Biosciences, Inc. (OTCQX: IDXG) (?Interpace?

Shared Services Agreement, dated August 31, 2022 by and among Interpace Biosciences, Inc., Interpace Pharma Solutions, Inc. and Flagship Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2022.

Exhibit 10.1 Execution Version SHARED SERVICES AGREEMENT This Shared Services Agreement, dated and effective as of August 31, 2022 (this ?Agreement?), is entered into between Interpace Pharma Solutions, Inc., a Delaware corporation (?Company?) and Interpace Biosciences, Inc., a Delaware corporation (?Shareholder? and collectively with Company, ?Seller?), and Flagship Biosciences, Inc. a Delaware l

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissi

Unaudited Pro Forma Condensed Consolidated Financial Information

Exhibit 99.2 Unaudited Pro Forma Condensed Consolidated Financial Information The unaudited pro forma condensed consolidated financial statements were prepared to assist readers in understanding the nature and effects of the sale (the ?Asset Sale?) by Interpace Biosciences, Inc., (the ?Company?), on August 31, 2022 of substantially all of the assets and the ongoing business comprising the Company?

Asset Purchase Agreement, dated August 31, 2022 by and among Interpace Biosciences, Inc., Interpace Pharma Solutions, Inc. and Flagship Biosciences, Inc., incorporated by reference to Exhibit 2.1 of the Company’s Current Report on Form 8-K filed with the SEC on September 7, 2022.

Exhibit 2.1 Execution Version ASSET PURCHASE AGREEMENT Asset Purchase Agreement (this ?Agreement?), dated this 31st day of August 2022 (the ?Execution Date?), by and among Flagship Biosciences, Inc., a Delaware corporation (the ?Purchaser?), Interpace Pharma Solutions, Inc., a Delaware corporation (the ?Company?), and Interpace Biosciences, Inc., a Delaware corporation (the ?Shareholder?). W I T N

Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved

Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved ? Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT? ? 2022 Year to Date Net Loss Improves by $1.5 million ? Days Sales Outstanding (DSO) decreased by 15% PARS

Robert Gorman Letter Agreement dated April 16, 2020, by and between Interpace Biosciences, Inc. and Robert Gorman, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on August 15, 2022.

Exhibit 10.1 April 16, 2020 Mr. Robert Gorman 109 Nutmeg Lane North Andover, MA 01845 RE: Election as Chairman of the Board of Directors Dear Bob, This letter (this ?Letter?) sets forth the terms and conditions of your service as Chairman of the Board of Directors (?Chairman?) (the ?Board?) of Interpace Biosciences, Inc. (the ?Company?), subject to your election as Chairman by the Nominating and C

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

300 Interpace Parkway | Morris Corporate Center 1, Building C | Parsippany, NJ 07054 Corporate Offices: (855) 776-6419 | Fax: (973) 265-0191 | [email protected]

RW 1 formrw.htm June 16, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Interpace Biosciences, Inc. Request to Withdraw Registration Statement on Form S-1 File No. 333-261504 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Interpace Biosciences, Inc., a

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except per share data)

Exhibit 99.1 Interpace Biosciences Announces First Quarter 2022 Financial and Business Results ? Q1 Revenue of $10.4 million up 6% versus Prior Year ? Q1 Net Loss improved $2 million versus Prior Year ? Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) ?Interpace Biosciences, Inc. (?Interpace? or the ?Company?) (OTCQX: IDXG) today announced financial resul

First Amendment to Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated as of May 5, 2022.

Exhibit 10.4 FIRST AMENDMENT TO SUBORDINATION AND INTERCREDITOR AGREEMENT This First Amendment to Subordination and Intercreditor Agreement (?First Amendment to Subordination Agreement?) is made as of May 5, 2022, by and between Comerica Bank (?Bank?) and the BroadOak Fund V, L.P. (?Creditor?). RECITALS A. Bank and Creditor entered into that certain Subordination and Intercreditor Agreement dated

Subordinated Convertible Promissory Note to BroadOak Fund V, L.P., dated May 5, 2022.

Exhibit 10.1 THIS INSTRUMENT AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR UPON RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer of in

First Amendment to Loan and Security Agreement and Consent with BroadOak Fund V, L.P. dated May 5, 2022 between Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, Interpace Pharma Solutions, Inc., and BroadOak Fund V, L.P.

Exhibit 10.3 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND CONSENT This First Amendment to Loan and Security Agreement and Consent (this ?Amendment?) is entered into as of May 5, 2022 between INTERPACE BIOSCIENCES, INC., a Delaware corporation (?Parent?), INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (?Diagnostics Corporation?), INTERPACE DIAGNOSTICS, LLC, a Delaware limited liabi

Consent Letter between Comerica Bank and Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC, and Interpace Pharma Solutions, Inc. dated May 5, 2022.

EX-10.2 3 ex10-2.htm Exhibit 10.2 May 5, 2022 Interpace Biosciences, Inc. Morris Corporate Center 1, Building C 300 Interpace Parkway Parsippany, NJ 07054 Attn: Thomas Freeburg RE: Loan and Security Agreement (as it may be amended, restated, modified, or supplemented from time to time, “Loan Agreement”), dated as of October 13, 2021, among Comerica Bank (“Bank”) and Interpace Biosciences, Inc., a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24

Letter from BDO USA, LP dated April 13, 2022, incorporated by reference to Exhibit 16.1 of the Company’s Current Report on Form 8-K, filed with the SEC on April 14, 2022.

EX-16.1 2 ex16-1.htm Exhibit 16.1 April 13, 2022 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 13, 2022, to be filed by our former client, Interpace Biosciences, Inc. We agree with the statements made in response to that Item insofar as they relate to our F

Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2022 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data)

Exhibit 99.1 Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results ? 2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ? 2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ? Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24249 Interpace Bios

IDXG / Interpace Diagnostics Group, Inc. / Singer Douglas Mark - INTERPACE BIOSCIENCES SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Interpace Biosciences, Inc. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 46062X303 (CUSIP Number) January 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

IDXG / Interpace Diagnostics Group, Inc. / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Interpace Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Peter H. Kamin 2720 Donald Ross Road, #311 Palm Beach Gardens, FL 33410 (Name, Address and Telephone Number of Person Authorized to Receive N

January 28, 2022

Exhibit 99.1 January 28, 2022 Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) ? Interpace Biosciences, Inc. (OTCQX: IDXG) (?Interpace? or the ?Company?) a leader in enabling personalized medicine, announced today that it was terminating its previously announced rights offering and th

Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2022 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

January 27, 2022

Exhibit 99.1 January 27, 2022 Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) ? Interpace Biosciences , Inc. (OTCQX: IDXG) (?Interpace?) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2

Agreement, dated January 21, 2022, between Dr. Vijay Aggarwal and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 27, 2022.

Exhibit 10.1 January 21, 2022 By Email [email protected] Vijay Aggarwal, Ph.D. 1200 Brentford Lane Malvern, Pennsylvania 19355-9776 Re: Interpace Biosciences, Inc. Dear Dr. Aggarwal: On behalf of Interpace Biosciences, Inc. (the ?Company?), I am very pleased to offer you the following terms and conditions in connection with your service on the board of directors (the ?Board?) of the Company shoul

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 21, 2022 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

As filed with the Securities and Exchange Commission on January 12, 2022

As filed with the Securities and Exchange Commission on January 12, 2022 Registration No.

IDXG / Interpace Diagnostics Group, Inc. / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Interpace Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Peter H. Kamin 2720 Donald Ross Road, #311 Palm Beach Gardens, FL 33410 (Name, Address and Telephone Number of Person Authorized to Receive N

Up to 4,200,045 Shares of Common Stock Issuable Upon the Exercise of Rights to Subscribe for such Shares at $6.65 per Share

Filed pursuant to Rule 424(b)(4) Registration No. 333-261504 PROSPECTUS Up to 4,200,045 Shares of Common Stock Issuable Upon the Exercise of Rights to Subscribe for such Shares at $6.65 per Share Interpace Biosciences, Inc. (the ?Company?, ?we?, ?us? or ?our?) is distributing to holders of our common stock, par value $0.01 per share, and holders of outstanding warrants we issued on January 25, 201

Interpace Biosciences, Inc. Morris Corporate Center 1, Building C 300 Interpace Parkway Parsippany, New Jersey 07054 January 10, 2022

Interpace Biosciences, Inc. Morris Corporate Center 1, Building C 300 Interpace Parkway Parsippany, New Jersey 07054 January 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tyler Howes Re: Interpace Biosciences, Inc. Registration Statement on Form S-1 SEC File No. 333-261504 Filed Decem

As filed with the Securities and Exchange Commission on January 7, 2022

As filed with the Securities and Exchange Commission on January 7, 2022 Registration No.

Form of Beneficial Owner Election Form.

Exhibit 99.6 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED JANUARY [?], 2022 (THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING (855) 793-5068. THE PROSPECTUS IS ALSO AVAILABLE ON THE COMPANY?S WEBSITE A

Form of Letter to Clients of Brokers and Nominees.

Exhibit 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEE HOLDERS INTERPACE BIOSCIENCES, INC. Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders and Certain Warrant Holders of Interpace Biosciences, Inc. January [?], 2022 To Our Clients: Enclosed for your consideration are materials relating to a rights offering by I

Form of Investor Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, to be entered into at the closing of the Standby Purchase Commitment.

Exhibit 10.68 INVESTOR RIGHTS AGREEMENT This Investor Rights Agreement (this ?Agreement?) dated as of [?], 2022, by and among Interpace Biosciences, Inc., a Delaware corporation (the ?Company?), 3K Limited Partnership, a Delaware limited partnership (the ?Standby Purchaser?), Peter H. Kamin, a natural person in his individual capacity (?Mr. Kamin?), Peter H. Kamin Revocable Trust dated February 20

Form of Notice of Guaranteed Delivery.

Exhibit 99.7 NOTICE OF GUARANTEED DELIVERY FOR NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATES ISSUED BY INTERPACE BIOSCIENCES, INC. This form, or one substantially equivalent hereto, must be used to exercise subscription rights (the ?Subscription Rights?) pursuant to the rights offering (the ?Rights Offering?) described in the Prospectus, dated January [?], 2022 (the ?Prospectus?), of Interpace

Form of Subscription Rights Certificate.

Exhibit 4.9 NUMBER OF RIGHTS: SUBSCRIPTION RIGHTS CERTIFICATE #: THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED JANUARY [?], 2022 (THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING (855) 793-5068. INTERPA

Form of Letter to Record Holders.

Exhibit 99.2 FORM OF LETTER TO RECORD HOLDERS OF COMMON STOCK AND WARRANTS INTERPACE BIOSCIENCES, INC. Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders and Certain Warrant Holders of Interpace Biosciences, Inc. January [?], 2022 Dear Record Holder: Enclosed are materials relating to a rights offering by Interpace Biosciences

Form of Standby Purchase Agreement by and among Interpace Biosciences, Inc., 3K Limited Partnership, Peter H. Kamin, Peter H. Kamin Revocable Trust dated February 2003, Peter H. Kamin Childrens Trust dated March 1997 and Peter H. Kamin Family Foundation, to be entered into upon the effectiveness of this registration statement.

Exhibit 10.66 STANDBY PURCHASE AGREEMENT by and among INTERPACE BIOSCIENCES, INC. and THE PARTIES NAMED HEREIN Dated as of [?], 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INTERPRETATION 2 Section 1.1 Definitions 2 Section 1.2 Interpretation 6 ARTICLE II THE RIGHTS OFFERING 6 Section 2.1 The Rights Offering. 6 Section 2.2 Subscription Price 7 Section 2.3 Standby Purchase Commitment 7 ART

Form of Registration Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, to be entered into at the closing of the Standby Purchase Commitment.

Exhibit 10.67 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT, dated as of [?], 2022 (this ?Agreement?), is by and among Interpace Biosciences, Inc., a Delaware corporation (the ?Company?), 3K Limited Partnership, a Delaware limited partnership (the ?Standby Purchaser?), Peter H. Kamin, a natural person in his individual capacity (?Mr. Kamin?), Peter H. Kamin Revocable Trust dated

Form of Instructions.

Exhibit 99.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED [?], 2022 (THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING (855) 793-5068. THE PROSPECTUS IS ALSO AVAILABLE ON THE COMPANY?S WEBSITE AT WWW.IN

Form of Letter to Brokers and Nominees.

Exhibit 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEE HOLDERS INTERPACE BIOSCIENCES, INC. Subscription Rights to Purchase Shares of Common Stock Offered Pursuant to Subscription Rights Distributed to Stockholders and Certain Warrant Holders of Interpace Biosciences, Inc. January [?], 2022 To Securities Dealers, Commercial Banks, Trust Companies and Other Nominees: This letter is being distribut

As filed with the Securities and Exchange Commission on January 3, 2022

As filed with the Securities and Exchange Commission on January 3, 2022 Registration No.

Form of Nominee Holder Certification.

Exhibit 99.5 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY?S PROSPECTUS DATED JANUARY [?], 2022 (THE ?PROSPECTUS?) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE SUBSCRIPTION AGENT, BY CALLING (855) 793-5068. THE PROSPECTUS IS ALSO AVAILABLE ON THE COMPANY?S WEBSITE A

IDXG / Interpace Diagnostics Group, Inc. / Kamin Peter Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Interpace Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Peter H. Kamin 2720 Donald Ross Road, #311 Palm Beach Gardens, FL 33410 (Name, Address and Telephone Number of Person Authorized to Receive N

As filed with the Securities and Exchange Commission on December 3, 2021

As filed with the Securities and Exchange Commission on December 3, 2021 Registration No.

IDXG / Interpace Diagnostics Group, Inc. / 1315 Capital II, L.P. Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X 303 (CUSIP Number) 1315 Capital II, L.P. 1315 Capital Management II, LLC 2929 Walnut Street, Suite 1240 Philadelphia, PA 19104 Telephone: (21

IDXG / Interpace Diagnostics Group, Inc. / Ampersand 2018 Limited Partnership - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Ampersand 2018 Limited Partnership AMP-18 Management Company Limited Partnership AMP-18 MC LLC 55 William Street, Suite 240 Wellesley, MA 02

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Inter

INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except per share data)

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results ● Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ● Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ● Second Consecutive Record Cash Collection Quarter ● Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ● Entered into $8 million t

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2021 INTERPACE BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated as of November 1, 2021, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.

Exhibit 10.3 SUBORDINATION AND INTERCREDITOR AGREEMENT This Subordination and Intercreditor Agreement (the ?Agreement?) is made as of November 1, 2021 by and between BroadOak Fund V, L.P. ( ?Creditor?) and COMERICA BANK (?Bank?). Recitals A. Interpace Biosciences, Inc., a Delaware corporation, Interpace Diagnostics Corporation, a Delaware corporation, Interpace Diagnostics, LLC, a Delaware limited

Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 29, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.

EX-10.1 2 ex10-1.htm Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of October 29, 2021 (the “Effective Date”) among BroadOak Fund V, L.P. (“Lender”), Interpace Biosciences, Inc., a Delaware corporation (“Parent”), Interpace Diagnostics Corporation, a Delaware corporation (“Diagnostics Corporation”), Interpace Diagnostics, LLC, a Delaware limi

First Amendment to Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated November 1, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021.

EX-10.2 3 ex10-2.htm Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND CONSENT This First Amendment to Loan and Security Agreement and Consent (“Amendment”) is entered into as of November 1, 2021 between Interpace Biosciences, Inc., a Delaware corporation (“Parent”), Interpace Diagnostics Corporation, a Delaware corporation (“Diagnostics Corporation”), Interpace Diagnostics, LLC, a D

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans

EX-99.1 5 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans PARSIPPANY, NJ, November 2, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fun

Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank

Exhibit 99.1 Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank PARSIPPANY, NJ, October 15, 2021 (GLOBE NEWSWIRE) ? Interpace Biosciences, Inc. (?Interpace? or the ?Company?) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new $7.5 Million revolving credit facility with Comerica Bank (the ?Bank?). The facility matures on Septe

Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021.

EX-10.1 2 ex10-1.htm Exhibit 10.1 INTERPACE BIOSCIENCES, INC. INTERPACE DIAGNOSTICS CORPORATION INTERPACE DIAGNOSTICS, LLC INTERPACE PHARMA SOLUTIONS, INC. LOAN AND SECURITY AGREEMENT October 13, 2021 This LOAN AND SECURITY AGREEMENT (this “Agreement”) is entered into as of October 13, 2021, by and between Comerica Bank, a Texas banking association (“Bank), Interpace Biosciences, Inc., a Delaware

Subordination Agreement by and between Ampersand 2018 Limited Partnership, 1315 Capital II. L.P., Comerica Bank Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021.

EX-10.2 3 ex10-2.htm Exhibit 10.2 SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of October 13, 2021, by and between the undersigned (“Creditor”) among each of the undersigned creditors (individually, a “Creditor” and, collectively, the “Creditors”) and Comerica Bank, a Texas banking association (“Bank”). Recitals A. Interpace Biosciences, Inc., a Delaware corpor

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 13, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

Fourth AMENDMENT TO SECURED PROMISSORY NOTE

EX-99.1 2 ex99-1.htm Exhibit 99.1 Fourth AMENDMENT TO SECURED PROMISSORY NOTE This Fourth Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of September 29, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Noteholde

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employe

FOURTH AMENDMENT TO SECURED PROMISSORY NOTE

Exhibit 99.2 FOURTH AMENDMENT TO SECURED PROMISSORY NOTE This Fourth Amendment to Secured Promissory Note (this ?Amendment?) is made and entered into as of September 29, 2021 (the ?Amendment Effective Date?) by and between Interpace Biosciences, Inc., a Delaware corporation (the ?Borrower?), and 1315 Capital II, L.P., a Delaware limited partnership (the ?Noteholder?). Capitalized terms used herein

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEF 14A 1 formdef14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14A-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 31, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) delaware 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer o

THIRD AMENDMENT TO SECURED PROMISSORY NOTE

EX-99.1 2 ex99-1.htm Exhibit 99.1 THIRD AMENDMENT TO SECURED PROMISSORY NOTE This Third Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of August 31, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Noteholder”).

THIRD AMENDMENT TO SECURED PROMISSORY NOTE

Exhibit 99.2 THIRD AMENDMENT TO SECURED PROMISSORY NOTE This Third Amendment to Secured Promissory Note (this ?Amendment?) is made and entered into as of August 31, 2021 (the ?Amendment Effective Date?) by and between Interpace Biosciences, Inc., a Delaware corporation (the ?Borrower?), and 1315 Capital II, L.P., a Delaware limited partnership (the ?Noteholder?). Capitalized terms used herein but

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 2) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-24249 Interpace BioSciences, Inc. (Exact name of registrant as spec

Troutman Pepper Hamilton Sanders LLP

CORRESP 1 filename1.htm Troutman Pepper Hamilton Sanders LLP 875 Third Avenue New York, NY 10022 troutman.com Merrill M. Kraines [email protected] August 20, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tara Harkins Kevin Kuhar Re: Interpace Biosciences, Inc. Form 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 3) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 3) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 000-24249 Interpace BioSciences, Inc. (Exact name of registrant as spec

Amendment to Secured Promissory Note dated May 10, 2021 with1315 Capital II, L.P., incorporated by reference to Exhibit 10.2 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.

EX-10.2 3 ex10-2.htm Exhibit 10.2 Execution Version AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of May 10, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and 1315 Capital II, L.P., a Delaware limited partnership (the “Noteholder”). Capitalize

Amendment to Security Agreement dated May 10, 2021 by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.

Exhibit 10.3 AMENDMENT TO SECURITY AGREEMENT This Amendment to Security Agreement (this ?Amendment?) is made and entered into as of May 10, 2021 (the ?Effective Date?) by and between Interpace Biosciences, Inc., a Delaware corporation (the ?Grantor?), and Ampersand 2018 Limited Partnership, a Delaware limited partnership in its capacity as collateral agent pursuant to the Notes (as hereinafter def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Interpace

Amendment to Secured Promissory Note dated May 10, 2021 with Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.

EX-10.1 2 ex10-1.htm Exhibit 10.1 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of May 10, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Noteholder”). Capitalized ter

Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results ● Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter ● Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ● Restructuring Exceeding Full-Year Savings Expectations ● On Track

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissi

Shareholder Director Nominations

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer of

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer of

SeCond AMENDMENT TO SECURED PROMISSORY NOTE

Exhibit 99.2 SeCond AMENDMENT TO SECURED PROMISSORY NOTE This Second Amendment to Secured Promissory Note (this ?Amendment?) is made and entered into as of June 25, 2021 (the ?Amendment Effective Date?) by and between Interpace Biosciences, Inc., a Delaware corporation (the ?Borrower?), and 1315 Capital II, L.P., a Delaware limited partnership (the ?Noteholder?). Capitalized terms used herein but

SECOND AMENDMENT TO SECURED PROMISSORY NOTE

EX-99.1 2 ex99-1.htm Exhibit 99.1 SECOND AMENDMENT TO SECURED PROMISSORY NOTE This Second Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of June 24, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and Ampersand 2018 Limited Partnership, a Delaware limited partnership (the “Noteholder”).

Amendment to Secured Promissory Note, dated May 10, 2021, by Interpace Biosciences, Inc. in favor of 1315 Capital II, L.P.

EX-4 2 ex4.htm Exhibit 4 Execution Version AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this “Amendment”) is made and entered into as of May 10, 2021 (the “Amendment Effective Date”) by and between Interpace Biosciences, Inc., a Delaware corporation (the “Borrower”), and 1315 Capital II, L.P., a Delaware limited partnership (the “Noteholder”). Capitalized terms u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X 303 (CUSIP Number) 1315 Capital II, L.P. 1315 Capital Management II, LLC 2929 Walnut Street, Suite 1240 Philadelphia, PA 19104 Telephone: (21

Amendment to the Security Agreement, dated May 10, 2021, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc.

Exhibit 5 AMENDMENT TO SECURITY AGREEMENT This Amendment to Security Agreement (this ?Amendment?) is made and entered into as of May 10, 2021 (the ?Effective Date?) by and between Interpace Biosciences, Inc.

Amendment to Secured Promissory Note, dated May 10, 2021, by and between Interpace Biosciences, Inc. and Ampersand 2018 Limited Partnership.

Exhibit 4 AMENDMENT TO SECURED PROMISSORY NOTE This Amendment to Secured Promissory Note (this ?Amendment?) is made and entered into as of May 10, 2021 (the ?Amendment Effective Date?) by and between Interpace Biosciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number)

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Ampersand 2018 Limited Partnership AMP-18 Management Company Limited Partnership AMP-18 MC LLC 55 William Street, Suite 240 Wellesl

Employment agreement entered into May 10, 2021, effective February 1, 2021, between Thomas Freeburg and the Company, incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.

EX-10.2 3 ex10-2.htm Exhibit 10.2 Employment Agreement This Employment Agreement (this “Agreement”) is made as of February 1, 2021 (the “Effective Date”) between Interpace Biosciences, Inc. (the “Company”) and Thomas Freeburg (“Executive”). The term of Executive’s employment under this Agreement will commence as of the Effective Date. Position. Executive’s full-time position will be Chief Financia

Interpace Biosciences Announces First Quarter 2021 Financial and Business Results

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces First Quarter 2021 Financial and Business Results ● Q1 Revenue of $9.8 Million is Company’s Highest as Combined Molecular Diagnostics and Pharma Services Business ● Q2 Revenue Expected to Exceed $11 million ● On Track to Exceed Full Year 2021 Revenue Growth of 35% ● Moving Up Target For EBITDA Breakeven from Q4 2021 to Q3 2021 PARSI

Security Agreement entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021, incorporated by reference to Exhibit 10.5 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.

EX-10.5 6 ex10-5.htm Exhibit 10.5 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this “Agreement”), is made by INTERPACE BIOSCIENCES, INC., a Delaware corporation (the “Grantor”), in favor of Ampersand 2018 Limited Partnership, a Delaware limited pa

Promissory Note entered into between the Company and 1315 Capital II, L.P, dated January 7, 2021, incorporated by reference to Exhibit 10.4 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.

EX-10.4 5 ex10-4.htm Exhibit 10.4 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH AC

Promissory Note entered into between the Company and Ampersand 2018 Limited Partnership, dated January 7, 2021,incorporated by reference to Exhibit 10.3 of the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.

EX-10.3 4 ex10-3.htm Execution Version Exhibit 10.3 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUI

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commission

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 Inter

Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021, incorporated by reference to Exhibit 2.1 of the Company’s Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021.

EX-2.1 2 ex2-1.htm Exhibit 2.1 ASSET PURCHASE AGREEMENT FOR NEW HAVEN LABORATORY BETWEEN INTERPACE BIOSCIENCES, INC. AND DIAMIR BIOSCIENCES, CORP. This ASSET PURCHASE AGREEMENT (“Agreement”) is made and entered into on March 16, 2021 by and between Interpace Biosciences, Inc., a Delaware corporation with an office located at Morris Corporate Center 1, Building C, 300 Interpace Parkway, Parsippany,

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 00

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commissio

Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results ● 2020 Full Year Net Revenue of $32.4 Million Up 34% vs Prior Year; Fourth Quarter Net Revenue of $9.6M Million Up 129% vs Prior Year; ● Provides Full Year 2021 Range of Revenues ● On Target to Achieve EBITDA Breakeven by 2021 Year End PARSIPPANY, NJ, March 31, 2021 (G

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 000-24249 Interpace

Lease Termination Notice to Meadows Landmark, LLC for the Company’s laboratory facility at Meadows Office Complex, 201 Route 17 North, Rutherford, New Jersey, effective March 31, 2021, incorporated by reference to Exhibit 10.73 of the Company’s Annual Report on Form 10-k for the year ended December 31, 2021, filed with the SEC on October April 1, 2021.

Exhibit 10.73 March 27, 2020 Via E-Mail Meadows Landmark, LLC c/o Onyx Equities 900 Route 9 North Woodbridge, New Jersey 07095 Attention: John H. Roeser and Samuel Giordano, CFO Re: Lease between Meadows Landmark, LLC and Interpace Biosciences, LLC - 201 Meadows Office Complex, 201 Rt. 17, North Rutherford, NJ Dear Mr. Roeser and Mr. Giordano: Pursuant to its obligations as set forth in Section 7

-

SEC FILE NUMBER 000-24249 CUSIP NUMBER 46062X 303 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Description of Securities, incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-K, filed with the SEC on April 1, 2021.

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 20, 2020, Interpace Biosciences, Inc. (the ?Company?, ?we?, ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, (the ?Exchange Act?) which consists of common stock, $0.01 par value per shar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. __)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Interpace Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Peter H. Kamin 2720 Donald Ross Road, #311 Palm Beach Gardens, FL 33410 (Name, Address and Telephone Number of Person Authorized to Receive No

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

Interpace Biosciences Announces Acceptance for Trading on the OTCQX

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Acceptance for Trading on the OTCQX PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of the Company’

Interpace Biosciences Announces Path Forward in Letter to Shareholders

Exhibit 99.1 Interpace Biosciences Announces Path Forward in Letter to Shareholders PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to shareholders: Dear Shareholders, As the newly appointed President and CEO of Interpace I want to take a moment to formally intr

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

Interpace Biosciences Announces Impending Delisting from Nasdaq

EX-99.2 3 ex99-2.htm Exhibit 99.2 Interpace Biosciences Announces Impending Delisting from Nasdaq PARSIPPANY, NJ, Feb. 17, 2021 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, today announced that on February 16, 2020 it had received notification from the Listing Qualifications Staff (the “Staff”) of The Nasd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Interpace Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Interpace Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 46062X303 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction (Commission (IRS Employer

Interpace Biosciences Announces CFO Leadership Transition

EX-99.1 3 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces CFO Leadership Transition PARSIPPANY, NJ, February 4, 2021 — Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”) a leader in enabling personalized medicine, announced today that its Board of Directors has appointed Tom Freeburg, Chief Accounting Officer, as Interpace’s Chief Financial Officer (“CFO”). Mr. Freeburg succeeds Fred

Severance agreement and General Release, dated January 31, 2021, by and between the Company and Fred Knechtel, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on October May 11, 2021.

EX-10.1 2 ex10-1.htm Exhibit 10.1 SEVERANCE AGREEMENT AND GENERAL RELEASE This Severance Agreement and General Release (this “Agreement”) is entered into by Fred Knechtel (“Executive”) and Interpace Biosciences, Inc. (the “Company”). Executive and the Company are jointly referred to in this Agreement as the “Parties” and both individually referred to in this Agreement as a “Party.” 1. Termination

-

As filed with the Securities and Exchange Commission on January 29, 2021 Registration No.

Secured Promissory Note, dated January 7, 2021, by Interpace Biosciences, Inc. in favor of 1315 Capital II, L.P. (incorporated by reference to Exhibit 2 to Amendment No. 2 to Schedule 13D filed by 1315 Capital II, L.P. on January 21, 2021).

Exhibit 2 Execution Version THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND SUCH LAWS.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46062X 303 (CUSIP Number) 1315 Capital II, L.P. 1315 Capital Management II, LLC 2929 Walnut Street, Suite 1240 Philadelphia, PA 19104 Telephone: (21

Security Agreement, dated January 7, 2021, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc. (incorporated by reference to Exhibit 3 to Amendment No. 2 to Schedule 13D filed by 1315 Capital II, L.P. on January 21, 2021).

EX-3 3 ex3.htm Exhibit 3 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this “Agreement”), is made by INTERPACE BIOSCIENCES, INC., a Delaware corporation (the “Grantor”), in favor of Ampersand 2018 Limited Partnership, a Delaware limited partnership

Results of Operations and Financial Condition, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-24249 I

Conference Call and Webcast Thursday January 21, 2021 at 4:30 pm ET

EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Third Quarter 2020 Financial and Business Results and Completion of $5 Million Bridge Loan ● Third Quarter Net Revenue of $8.2 Million Up 7% vs Prior Year; Third Quarter Year to Date Net Revenue of $22.8 Million Up 14% vs Prior Year ● Estimates Fourth Quarter Net Revenue range of $9.0 million - $10.0 million ● Realized Reimbursement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number)

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERPACE BIOSCIENCES, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 46062X303 (CUSIP Number) Ampersand 2018 Limited Partnership AMP-18 Management Company Limited Partnership AMP-18 MC LLC 55 William Street, Suite 240 Wellesl

Fifth Amendment to Lease, dated June 15, 2009, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

Exhibit 10.52 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (the “Amendment”), made as of the 15th day of June, 2009, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into a certain Lease dated as of June 12, 2004

Second Amendment to Lease, dated June 17, 2005, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.49 12 ex10-49.htm Exhibit 10.49 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (the “Amendment”), made as of June 17, 2005, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into a certain Lease dated as of

Secured Promissory Note, dated January 7, 2021, by Interpace Biosciences, Inc. in favor of Ampersand 2018 Limited Partnership (incorporated by reference to Exhibit 2 to Amendment No. 3 to Schedule 13D filed by Ampersand 2018 Limited Partnership on January 19, 2021).

EX-99.2 2 d112946dex992.htm EX-99.2 Exhibit 2 Execution Version THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGIST

Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.

EX-21.1 23 ex21-1.htm Exhibit 21.1 Interpace Biosciences, Inc. Subsidiaries Interpace Diagnostics, LLC, a Delaware limited liability company, is a wholly-owned subsidiary of Interpace Biosciences, Inc. Interpace Diagnostics Corporation, a Delaware corporation, is a wholly-owned subsidiary of Interpace Diagnostics, LLC. Interpace Diagnostics Lab Inc., a Delaware corporation, is a wholly-owned subsi

Seventh Amendment to Lease, dated October 26, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.54 17 ex10-54.htm Exhibit 10.54 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (the “Seventh Amendment to Lease”), made as of the 20th day of October, 2010, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”), WITNESSETH WHEREAS, Landlord and Tenant: enter

Fourth Amendment to Lease, dated December 20, 2007, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

Exhibit 10.51 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (the “Amendment”) made as of the 20th day of December, 2007, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”) and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSTH WHEREAS, Landlord and Tenant entered into a certain Lease dated as of June 12, 2

Third Amendment to Lease, dated May 25, 2006, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.50 13 ex10-50.htm Exhibit 10.50 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (the “Amendment”), made as of the 25th day of May, 2006, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into a certain Lease da

Lease Agreement, dated June 12, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.47 10 ex10-47.htm Exhibit 10.47 SOUTHPORT - GENTRIS CORPORATION LEASE OF SECOND GENERATION SPACE IN A SINGLE STORY FLEX BUILDING ARTICLE DESCRIPTION 1 BASIC PROVISIONS 2 ADDITIONAL RENT 3 LANDLORD’S ADDITIONAL WORK 4 USE OF THE PROPERTY BY THE TENANT 5 REPAIRS AND MAINTENANCE BY THE TENANT 6 REPAIRS AND MAINTENANCE BY THE LANDLORD 7 COMMON AREAS 8 INSURANCE AND INDEMNITY 9 LANDLORD’S RESERVE

Tenth Amendment to Lease, dated July 15, 2014, by and among Southport Business Park Limited Partnership, Gentris Corporation, and Gentris, LLC, filed herewith.

EX-10.57 20 ex10-57.htm Exhibit 10.57 TENTH AMENDMENT TO LEASE ASSIGNMENT, ASSUMPTION, and CONSENT TO ASSIGNMENT THIS TENTH AMENDMENT TO LEASE, ASSIGNMENT, ASSUMPTION, AND CONSENT TO ASSIGNMENT (the “Tenth Amendment to Lease”), made as of the 15th day of July, 2014, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPOR

Description of Securities, filed herewith.

EX-4.1 3 ex4-1.htm Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 20, 2020, Interpace Biosciences, Inc. (the “Company”, “we”, “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) which consists of common stock, $0.01

First Amendment, dated September 26, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, filed herewith.

EX-10.36 6 ex10-36.htm Exhibit 10.36 FIRST LEASE AMENDMENT THIS FIRST LEASE AMENDMENT (this “Amendment”) is made and entered into as of September 26th, 2017 by and between SADDLE LANE REALTY, LLC, a Pennsylvania limited liability company (the “Landlord”) and INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSTH: WHEREAS, the Landlord and the Tenant are parties to that

Termination Agreement, dated July 9, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc.

EX-10.3 4 ex10-3.htm Exhibit 10.3 TERMINATION AGREEMENT This Termination Agreement (this “Agreement”), is made and entered into on July 9, 2020, by and between Ampersand 2018 Limited Partnership, a Delaware limited partnership (“Ampersand”), and Interpace Biosciences, Inc., a Delaware corporation (the “Company”). Ampersand and the Company are sometimes referred to individually as a “Party” and col

Office Lease Agreement, dated October 9, 2007, by and between Meadows Office, L.L.C. and Cancer Genetics, Inc., incorporated by reference to Exhibit 10.44 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time.

EX-10.44 7 ex10-44.htm Exhibit 10.44 OFFICE LEASE AGREEMENT BETWEEN MEADOWS OFFICE, L.L.C. AS LANDLORD AND CANCER GENETICS, INC. AS TENANT DATED OCTOBER 9, 2007 TABLE OF CONTENTS 1 Definitions and Basic Lease Provisions 4 2 Lease Grant 4 3 Tender of Possession 4 4 Rent 5 5 Delinquent Payment; Handling Charges 5 6 Security Deposit 5 7 Services; Utilities; Common Areas 6 (a) Services 6 (b) Excess Ut

Ninth Amendment to Lease, dated November 7, 2012, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.56 19 ex10-56.htm Exhibit 10.56 NINTH AMENDMENT TO LEASE THIS NINTH AMENDMENT TO LEASE (the “Ninth Amendment to Lease”), made as of the 7th day of November, 2012, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into

Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, filed herewith.

EX-10.8 2 ex10-8.htm Exhibit 10.8 AMENDMENT TO THE INTERPACE BIOSCIENCES, INC. 2019 EQUITY INCENTIVE PLAN The Interpace Biosciences, Inc. 2019 Equity Incentive Plan (the “Plan”) is hereby amended, effective as of the date of adoption of this Amendment by the Board of Directors of Interpace Biosciences, Inc. (the “Company”): 1. Section 3(a) of the Plan is amended in its entirety; provided that Sect

Conformed version of Certificate of Incorporation of Interpace Biosciences, Inc., as amended by the Certificate of Amendment, effective January 15, 2020, and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020, filed herewith.

Exhibit 3.1 Certificate of Incorporation of Professional Detailing, Inc. The undersigned, being a natural person, solely for the purpose of organizing a corporation under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereof and supplemental thereto, and known, identified and referre

Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, filed herewith.

EX-10.9 3 ex10-9.htm Exhibit 10.9 INTERPACE BIOSCIENCES, INC. 2019 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE AND RESTRICTED STOCK UNIT AGREEMENT Interpace Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its 2019 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Participant”) an award of the number

Letter Amendment, dated October 21, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.48 11 ex10-48.htm Exhibit 10.48 October 21, 2004 Mr. Michael Murphy Gentris Corporation 133 Southcenter Court, St, 400 Morrisville, NC 27560 Dear Michael: Under Exhibit B-2 of our lease with Gentris, your company is given an option of adding change orders to the original tenant improvement contract of up to $10,000. For each $5,000 of tenant improvement money that is amortized into the rent,

Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc., filed herewith.

EX-10.46 9 ex10-46.htm Exhibit 10.46 CONSENT TO ASSIGNMENT This Consent to Assignment (this “Agreement”) is executed as of July 19, 2019, between Meadows Landmark LLC, a Delaware limited liability company (“Landlord”), Cancer Genetics, Inc., a Delaware corporation (“Assignor”), Interpace BioPharma, Inc., a Delaware corporation (“Assignee”). RECITALS: A. Assignor is the tenant under a certain Offic

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file Number: 00

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num

Sixth Amendment to Lease, dated June 3, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

EX-10.53 16 ex10-53.htm Exhibit 10.53 SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (the “Sixth Amendment to Lease”), made as of the 3rd day of June, 2010, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into a c

Amendment No. 8 to Lease, dated December 31, 2019, by and between WE 2 Church Street South LLC and Interpace Diagnostics Lab Inc., filed herewith.

EX-10.34 5 ex10-34.htm Exhibit 10.34 AMENDMENT NO. 8 TO LEASE THIS AMENDMENT NO. 8 TO LEASE (this “Amendment”) is made and entered into as of the 31 day of December, 2019 by and between Landlord and Tenant named below: LANDLORD: WE 2 Church Street South LLC c/o Winstanley Enterprises LLC 150 Baker Avenue Extension, Suite 303 Concord, Massachusetts 01742 TENANT: Interpace Diagnostics Lab Inc. 2 Chu

Eighth Amendment to Lease, dated July 27, 2011, by and between Southport Business Park Limited Partnership and Gentris Corporation, filed herewith.

Exhibit 10.55 EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (the “Eighth Amendment to Lease”), made as of the 21th day of July, 2011, by and between SOUTHPORT BUSINESS PARK LIMITED PARTNERSHIP, a North Carolina limited partnership (the “Landlord”), and GENTRIS CORPORATION, a Delaware corporation (the “Tenant”). WITNESSETH WHEREAS, Landlord and Tenant entered into a certain lease dated a

Assignment of Lease, dated July 15, 2019, by and between Cancer Genetics, Inc. and Interpace BioPharma, Inc., filed herewith.

EX-10.58 21 ex10-58.htm Exhibit 10.58 STATE OF NORTH CAROLINA ASSIGNMENT OF LEASE COUNTY OF WAKE THIS ASSIGNMENT OF LEASE (“Assignment”) is entered into and effective this 15th day of July, 2019· (“Effective Date”) by and between Cancer Genetics, Inc., a Delaware corporation, successor-in-interest to Gentris, LLC, a Delaware limited liability company, (hereinafter the “Assignor”) and Interpace Bio

Security Agreement, dated January 7, 2021, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc. (incorporated by reference to Exhibit 3 to Amendment No. 3 to Schedule 13D filed by Ampersand 2018 Limited Partnership on January 19, 2021).

EX-99.3 Exhibit 3 Execution Version SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of January 7, 2021 (as amended, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this “Agreement”), is made by INTERPACE BIOSCIENCES, INC., a Delaware corporation (the “Grantor”), in favor of Ampersand 2018 Limited Partnership, a Delaware limited partnership, in it

First Loan Modification Agreement, dated March 18, 2019, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc. (n/k/a Interpace Biosciences, Inc.), Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC.

Exhibit 10.6 FIRST LOAN MODIFICATION AGREEMENT This First Loan Modification Agreement (this “Loan Modification Agreement”) is entered into as of March 18, 2019, by and among (a) SILICON VALLEY BANK, a California corporation (“Bank”) and (b) (i) INTERPACE DIAGNOSTICS GROUP, INC., a Delaware corporation (“IDG”), (ii) INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“IDC”), and (iii) INTERP

Support Agreement, dated April 2, 2020, by and between 1315 Capital II, L.P. and Interpace Biosciences, Inc.

Exhibit 10.2 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”) is entered into as of April 2, 2020, by and between 1315 Capital II, L.P., a Delaware limited partnership (“1315 Capital”), and Interpace Biosciences, Inc., a Delaware corporation (the “Company”). BACKGROUND WHEREAS, pursuant to a Securities Purchase and Exchange Agreement, dated as of January 10, 2020, the Company issued, so

Support Agreement, dated April 7, 2020, by and between Ampersand 2018 Limited Partnership and Interpace Biosciences, Inc.

Exhibit 10.1 SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”) is entered into as of April 7, 2020, by and between Ampersand 2018 Limited Partnership, a Delaware limited partnership (“Ampersand”), and Interpace Biosciences, Inc., a Delaware corporation (the “Company”). BACKGROUND WHEREAS, pursuant to a Securities Purchase and Exchange Agreement, dated as of January 10, 2020, the Company

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number

First Amendment to Lease, dated October 30, 2017, by and between Meadows Landmark LLC and Cancer Genetics, Inc., filed herewith.

Exhibit 10.45 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (the “Amendment”) is entered into this 30 day of October, 2017 (the “Effective Date”), between MEADOWS LANDMARK LLC, a Delaware limited liability company (“Landlord”), and CANCER GENETICS, INC., a Delaware corporation (“Tenant”). Landlord and Tenant are parties to a certain Office Lease Agreement dated October 9, 2007 (the “Lease

Guaranty of Lease, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Southport Business Park Limited Partnership, filed herewith.

EX-10.59 22 ex10-59.htm Exhibit 10.59 GUARANTY OF LEASE This Guaranty of Lease (“Guaranty”) is given as of July 15, 2019 by Interpace Diagnostics Group, Inc., a Delaware corporation (“Guarantor”) in favor of Southport Business Park Limited Partnership, a North Carolina limited partnership (“Landlord”). RECITALS A. Cancer Genetics, Inc., a Delaware corporation (“Assignor”) successor-in-interest to

Loan and Security Agreement, dated November 13, 2018, by and among Silicon Valley Bank, Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC, filed herewith.

EX-4.9 4 ex4-9.htm Exhibit 4.9 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 13, 2018 (the “Effective Date”), by and among (a) SILICON VALLEY BANK, a California corporation (“Bank”), and (b) (i) INTERPACE DIAGNOSTICS GROUP, INC., a Delaware corporation (“IDG”), (ii) INTERPACE DIAGNOSTICS CORPORATION, a Delaware corporation (“IDC”), and (iii) I

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Termination of a Material Definitive Agreement

8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 5, 2021 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorp

Material Impairments, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2020 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commiss

Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor

Exhibit 99.1 Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor Parsippany, NJ, Nov. 25, 2020 – Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December 31, 2020. He will be replaced as President and Chief Ex

Employment Agreement, dated November 23, 2020, between Thomas W. Burnell and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020.

Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on November 23, 2020, by and between Interpace Biosciences, Inc. (the “Company”) and Thomas W. Burnell (“Executive”), collectively referred to herein as the “Parties.” WHEREAS, the Company desires to employ Executive as its Chief Executive Officer and Executive desires to serve in such capacity on behalf

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2020 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incor

Separation and Consulting Agreement and General Release, dated November 23, 2020, between Jack E. Stover and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020.

Exhibit 10.2 SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE This Separation and Consulting Agreement and General Release (this “Agreement”), dated November 23, 2020 (the “Effective Date”), is entered into by Jack E. Stover (“Executive”) and Interpace Biosciences, Inc. (the “Company”). Executive and the Company are jointly referred to in this Agreement as the “Parties” and both individuall

Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing

Exhibit 99.1 Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing PARSIPPANY, NJ, November 19, 2020 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indica

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2020 INTERPACE Biosciences, INC. (Exact name of Registrant as specified in its charter) DELAWARE 0-24249 22-2919486 (State or other jurisdiction of incorporation) (Commis

-

SEC FILE NUMBER 000-24249 CUSIP NUMBER 46062X 303 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.